Profile of delamanid for the treatment of multidrug-resistant tuberculosis

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 677-682

  Szumowsk, John D ^a,b   Lynch, John B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Delamanid; Deltyba; OPC 67683; Tuberculosis

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; DELAMANID; EFAVIRENZ; ETHAMBUTOL; LEVOFLOXACIN; LOPINAVIR; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RITONAVIR; STREPTOMYCIN; TENOFOVIR; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

COLONY FORMING UNIT; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTICENTER STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL; QT PROLONGATION; REVIEW; SPUTUM CULTURE; TREATMENT DURATION; ANIMAL; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG INTERACTION; LONG QT SYNDROME; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; RISK ASSESSMENT; RISK FACTOR; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; LONG QT SYNDROME; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; RISK ASSESSMENT; RISK FACTORS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84922169897     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S60923     Document Type: Review

References (28)

1. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med. 2013;368(8):745–755.
2. Multidrug-resistant tuberculosis (MDR-TB) 2014 Update. World Health Organization; 2014.
3. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300.
4. Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis. 2014;14(4):327–340.
5. Dooley KE, Nuermberger EL, Diacon AH. Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS. 2013;8(6):579–585.
6. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466.
7. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962–966.
8. Assessment report Deltyba, Procedure No.: EMEA/H/C/002552. European Medicines Agency, Committee for Medicinal Products for Human Use; 2013.
9. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011;15(7):949–954.
10. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med. 2007;4(3):e120.
11. Saliu OY, Crismale C, Schwander SK, Wallis RS. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J Antimicrob Chemother. 2007;60(5):994–998.
12. Shimokawa Y, Sasahara K, Yoda N, Mizuno K, Umehara K. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro. Biol Pharm Bull. 2014;37(11):1727–1735.
13. Deltyba EPAR Product Information, Annex I summary of product characteristics. European Medicines Agency, Committee for Medicinal Products for Human Use; 2014.
14. Esposito S, D’Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J. 2014;44(3):811–815.
15. Doi N, Disratthakit A. Characteristic Anti-Mycobacterial Spectra of the Novel Anti-TB Drug Candidates OPC-67683 and PA-824. Interscience Conference on Antimicrobial Agents and Chemotherapy 2006; San Francisco, CA.
16. Paccaly AJ, Petersen C, Patil S, et al. Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects. 19th International AIDS Conference; 2012.
17. Sasaki H, Haraguchi Y, Itotani M, et al. Synthesis and antitu-berculosis activity of a novel series of optically active 6-nitro-2, 3-dihydroimidazo[2,1-b]oxazoles. J Med Chem. 2006;49(26): 7854–7860.
18. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41(6):1393–1400.
19. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151–2160.
20. Zhang Q, Liu Y, Tang S, Sha W, Xiao H. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China. Cell Biochem Biophys. 2013;67(3):957–963.
21. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis. 1993;147(4):1062–1063.
22. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144(9):650–659.
23. Rodriguez M, Monedero I, Caminero JA, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis. 2013;17(4):520–525.
24. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43(12): 1603–1611.
25. Diacon AH, von Groote-Bidlingmaier F, Donald PR. Delamanid, a new 6-nitro-2,3-dihydroimidazo[2,1-b] oxazole for the management of tuberculosis resistant to at least isoniazid and rifampicin. Expert Opin Orphan Drugs. 2014;2(1):87–94.
26. Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Ye w WW, Lange C, Chang KC. Novel drugs against tuberculosis: a clinician’s perspective. Eur Respir J. Epub 2014 Nov 27.
27. Warner DF, Mizrahi V. Shortening treatment for tuberculosis: to basics. N Engl J Med. 2014;371(17):1642–1643.
28. Delamanid [webpage on the internet]. Available from: http://www. chemspider.com/Chemical-Structure.4981055.html. Accessed January 8, 2015.